@Untiti14 @SeeFisch Brother, of course entresto is superior to ARB/ACEi. BB’s are a different class of drug completely. Sacubitril is added to an ARB, thats all entresto is. Expensive? yes, but it is superior, no question. See trial below. https://t.co/Y
RT @gcfmd: @mikejohansenmd @JavedButler1 Here is a clinical practice based observational analysis on outcomes for ARNI vs ACEI/ARB. Agree…
@mikejohansenmd @JavedButler1 Here is a clinical practice based observational analysis on outcomes for ARNI vs ACEI/ARB. Agree analyses of adherence and persistence of GDMT would be informative. We have one underway. https://t.co/Sgzx3aZW3j https://t.c
RT @JACCJournals: Does sacubitril-valsartan lead to better #HFrEF outcomes compared to ACEi/ARB therapy in real world clinical practice? Dr…
RT @JACCJournals: Does sacubitril-valsartan lead to better #HFrEF outcomes compared to ACEi/ARB therapy in real world clinical practice? Dr…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction https://t.co/m2VouYg7ni
Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction https://t.co/m2VouXYvYI
RT @Cardio_delaGuia: Estudio USA 🇺🇸 @JACCJournals 👴🏼👴🏿 Sacubitril-valsartán se asoció con menor riesgo de muerte y hospitalización vs IECA…
RT @Cardio_delaGuia: Estudio USA 🇺🇸 @JACCJournals 👴🏼👴🏿 Sacubitril-valsartán se asoció con menor riesgo de muerte y hospitalización vs IECA…
RT @Cardio_delaGuia: Estudio USA 🇺🇸 @JACCJournals 👴🏼👴🏿 Sacubitril-valsartán se asoció con menor riesgo de muerte y hospitalización vs IECA…
RT @Cardio_delaGuia: Estudio USA 🇺🇸 @JACCJournals 👴🏼👴🏿 Sacubitril-valsartán se asoció con menor riesgo de muerte y hospitalización vs IECA…
RT @Cardio_delaGuia: Estudio USA 🇺🇸 @JACCJournals 👴🏼👴🏿 Sacubitril-valsartán se asoció con menor riesgo de muerte y hospitalización vs IECA…
RT @Cardio_delaGuia: Estudio USA 🇺🇸 @JACCJournals 👴🏼👴🏿 Sacubitril-valsartán se asoció con menor riesgo de muerte y hospitalización vs IECA…
RT @Cardio_delaGuia: Estudio USA 🇺🇸 @JACCJournals 👴🏼👴🏿 Sacubitril-valsartán se asoció con menor riesgo de muerte y hospitalización vs IECA…
RT @Cardio_delaGuia: Estudio USA 🇺🇸 @JACCJournals 👴🏼👴🏿 Sacubitril-valsartán se asoció con menor riesgo de muerte y hospitalización vs IECA…
Ojalá llegue a Venezuela
Estudio USA 🇺🇸 @JACCJournals 👴🏼👴🏿 Sacubitril-valsartán se asoció con menor riesgo de muerte y hospitalización vs IECA/ARB en una cohorte heterogénea de pacientes blancos con insuficiencia cardíaca sistólica, con resultados similares en pacientes negros h
RT @BSHeartFailure: Always made slightly uncomfortable by propensity matching in observational studies, but here's one showing benefit for…
RT @BSHeartFailure: Always made slightly uncomfortable by propensity matching in observational studies, but here's one showing benefit for…
Nice study confirming efficacy of Entresto in HF, but demonstrating no benefit in Blacks. Not surprising considering lack of Blacks in PARADIGM (5%). Need (a) more diversity in RCTs, (b) more appreciation of #realworldevidence, or (c) both to ensure new th
RT @BSHeartFailure: Always made slightly uncomfortable by propensity matching in observational studies, but here's one showing benefit for…
RT @BSHeartFailure: Always made slightly uncomfortable by propensity matching in observational studies, but here's one showing benefit for…
RT @BSHeartFailure: Always made slightly uncomfortable by propensity matching in observational studies, but here's one showing benefit for…
RT @BSHeartFailure: Always made slightly uncomfortable by propensity matching in observational studies, but here's one showing benefit for…
Always made slightly uncomfortable by propensity matching in observational studies, but here's one showing benefit for sac-val in a large number of "real life" patients with LVSD. JACC Heart Failure 2020 https://t.co/Rhzcc2I1tt
RT @JonathanDavisHF: More data: Sacubitril-valsartan is better than ACE/ARB in large comparative effectiveness study. Switch!! BUT, only 20…
RT @JACCJournals: Does sacubitril-valsartan lead to better #HFrEF outcomes compared to ACEi/ARB therapy in real world clinical practice? Dr…
Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction https://t.co/m2VouYg7ni
RT @JonathanDavisHF: More data: Sacubitril-valsartan is better than ACE/ARB in large comparative effectiveness study. Switch!! BUT, only 20…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
RT @ATRIUMRx: Spoiler alert: ARNI is better than ACE/ARB in real life. Interestingly, not shown to be better in black patients, but consis…
RT @JonathanDavisHF: More data: Sacubitril-valsartan is better than ACE/ARB in large comparative effectiveness study. Switch!! BUT, only 20…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
RT @ATRIUMRx: Spoiler alert: ARNI is better than ACE/ARB in real life. Interestingly, not shown to be better in black patients, but consis…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
RT @icorvilud: More evidence is needed on the statistic value of propensity matching for real world data studies. Probably different popula…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
RT @JACCJournals: Does sacubitril-valsartan lead to better #HFrEF outcomes compared to ACEi/ARB therapy in real world clinical practice? Dr…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
More evidence is needed on the statistic value of propensity matching for real world data studies. Probably different populations receive different treatments and one of the arms gives better improvements leading to equal final prognosis. #sacubitril/valsa
RT @ATRIUMRx: Spoiler alert: ARNI is better than ACE/ARB in real life. Interestingly, not shown to be better in black patients, but consis…
RT @ATRIUMRx: Spoiler alert: ARNI is better than ACE/ARB in real life. Interestingly, not shown to be better in black patients, but consis…
RT @AnaSaucePer: Sacubitril/valsartán vs IECA/ARA en pacientes con IC sistólica, cohorte que incluyo 7893 pacientes, S/V se asoció a un me…
RT @JACCJournals: Does sacubitril-valsartan lead to better #HFrEF outcomes compared to ACEi/ARB therapy in real world clinical practice? Dr…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
Spoiler alert: ARNI is better than ACE/ARB in real life. Interestingly, not shown to be better in black patients, but consisted of only ~20% of patients in the analysis. Substantial need for more research in this population. #cardiotwitter
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
RT @AnaSaucePer: Sacubitril/valsartán vs IECA/ARA en pacientes con IC sistólica, cohorte que incluyo 7893 pacientes, S/V se asoció a un me…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
RT @JonathanDavisHF: More data: Sacubitril-valsartan is better than ACE/ARB in large comparative effectiveness study. Switch!! BUT, only 20…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
RT @JonathanDavisHF: More data: Sacubitril-valsartan is better than ACE/ARB in large comparative effectiveness study. Switch!! BUT, only 20…
RT @JonathanDavisHF: More data: Sacubitril-valsartan is better than ACE/ARB in large comparative effectiveness study. Switch!! BUT, only 20…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
RT @JonathanDavisHF: More data: Sacubitril-valsartan is better than ACE/ARB in large comparative effectiveness study. Switch!! BUT, only 20…
RT @JonathanDavisHF: More data: Sacubitril-valsartan is better than ACE/ARB in large comparative effectiveness study. Switch!! BUT, only 20…
RT @JonathanDavisHF: More data: Sacubitril-valsartan is better than ACE/ARB in large comparative effectiveness study. Switch!! BUT, only 20…
RT @JonathanDavisHF: More data: Sacubitril-valsartan is better than ACE/ARB in large comparative effectiveness study. Switch!! BUT, only 20…
More data: Sacubitril-valsartan is better than ACE/ARB in large comparative effectiveness study. Switch!! BUT, only 20% African American, highlighting equity gap in our clinical trial enrollment. @gcfmd @AndrewJSauer @AminYehyaMD @IAmDrIbrahim @iamritu @Sh
RT @JACCJournals: Does sacubitril-valsartan lead to better #HFrEF outcomes compared to ACEi/ARB therapy in real world clinical practice? Dr…
RT @AnaSaucePer: Sacubitril/valsartán vs IECA/ARA en pacientes con IC sistólica, cohorte que incluyo 7893 pacientes, S/V se asoció a un me…
RT @AnaSaucePer: Sacubitril/valsartán vs IECA/ARA en pacientes con IC sistólica, cohorte que incluyo 7893 pacientes, S/V se asoció a un me…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
RT @JACCJournals: Does sacubitril-valsartan lead to better #HFrEF outcomes compared to ACEi/ARB therapy in real world clinical practice? Dr…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
RT @JACCJournals: Does sacubitril-valsartan lead to better #HFrEF outcomes compared to ACEi/ARB therapy in real world clinical practice? Dr…
RT @Cardio_delaGuia: Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia…
Estudio @JACCJournals que compara en vida real la efectividad de sacubitril-valsartán frente IECA/ARB en insuficiencia cardíaca sistólica: ✅SV se asoció con menores riesgos de muerte y hospitalización en esta comparación en una cohorte heterogénea. https:/
Sacubitril/valsartán vs IECA/ARA en pacientes con IC sistólica, cohorte que incluyo 7893 pacientes, S/V se asoció a un menor riesgo de muerte y hospitalización como lo mostró PARADIGM HF, sin embargo no se observó diferencias en pacientes de raza negra.
RT @JACCJournals: Does sacubitril-valsartan lead to better #HFrEF outcomes compared to ACEi/ARB therapy in real world clinical practice? Dr…
RT @JACCJournals: Does sacubitril-valsartan lead to better #HFrEF outcomes compared to ACEi/ARB therapy in real world clinical practice? Dr…
RT @JACCJournals: Does sacubitril-valsartan lead to better #HFrEF outcomes compared to ACEi/ARB therapy in real world clinical practice? Dr…
RT @JACCJournals: Does sacubitril-valsartan lead to better #HFrEF outcomes compared to ACEi/ARB therapy in real world clinical practice? Dr…
RT @JACCJournals: Does sacubitril-valsartan lead to better #HFrEF outcomes compared to ACEi/ARB therapy in real world clinical practice? Dr…
RT @JACCJournals: Does sacubitril-valsartan lead to better #HFrEF outcomes compared to ACEi/ARB therapy in real world clinical practice? Dr…
RT @JACCJournals: Does sacubitril-valsartan lead to better #HFrEF outcomes compared to ACEi/ARB therapy in real world clinical practice? Dr…
Dados da vida real sobre a utilização de Sacubitril/Valsartan. Para aprender como usar e titular no dia-a-dia inscreve-te nos EssentialCourses!! #EssentialCourses
Does sacubitril-valsartan lead to better #HFrEF outcomes compared to ACEi/ARB therapy in real world clinical practice? Dr. @ShannonMDunlay et al. provide a comparative analysis in #JACCHF with an editorial by Drs. @_adevore and @texhern. https://t.co/yqmea
@deepdev511 @ATRIUMRx Recent claims data analysis suggests that black patients (21% of the cohort) with HFrEF may not derive additional benefit from sacubitril/valsartan over ACEi/ARB. https://t.co/svhjwybgdo
RT @JTLLERGO: 📌Sacubitril-valsartan vs ACE/ARB in HF patients in clinical practice (🇺🇸 7,893 matched pairs) 📍 Lower risks of all-cause mort…
RT @paomorejon: 📌Sac/Val vs ACEIs/ARBs in #HFrEF •Propensity score •Mean FU👉🏻6 months •More hypotension (sav/val) ⚠️Concerning: lack of ef…
Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in HFrEF | JACC Very clever design 😉 We know that ACE/ARB combo does not reduce mortality in HFrEF but entresto does! https://t.co/OKFCVF16ED https://t.co/uwUC6mZgSc
RT @JTLLERGO: 📌Sacubitril-valsartan vs ACE/ARB in HF patients in clinical practice (🇺🇸 7,893 matched pairs) 📍 Lower risks of all-cause mort…
RT @paomorejon: 📌Sac/Val vs ACEIs/ARBs in #HFrEF •Propensity score •Mean FU👉🏻6 months •More hypotension (sav/val) ⚠️Concerning: lack of ef…
RT @ValleAlfonso: Sacubitril-valsartan was associated with lower risks of death and hospitalization compared with ACE/ARB in a heterogeneou…
RT @paomorejon: 📌Sac/Val vs ACEIs/ARBs in #HFrEF •Propensity score •Mean FU👉🏻6 months •More hypotension (sav/val) ⚠️Concerning: lack of ef…
RT @paomorejon: 📌Sac/Val vs ACEIs/ARBs in #HFrEF •Propensity score •Mean FU👉🏻6 months •More hypotension (sav/val) ⚠️Concerning: lack of ef…
RT @paomorejon: 📌Sac/Val vs ACEIs/ARBs in #HFrEF •Propensity score •Mean FU👉🏻6 months •More hypotension (sav/val) ⚠️Concerning: lack of ef…
RT @paomorejon: 📌Sac/Val vs ACEIs/ARBs in #HFrEF •Propensity score •Mean FU👉🏻6 months •More hypotension (sav/val) ⚠️Concerning: lack of ef…
RT @paomorejon: 📌Sac/Val vs ACEIs/ARBs in #HFrEF •Propensity score •Mean FU👉🏻6 months •More hypotension (sav/val) ⚠️Concerning: lack of ef…
RT @paomorejon: 📌Sac/Val vs ACEIs/ARBs in #HFrEF •Propensity score •Mean FU👉🏻6 months •More hypotension (sav/val) ⚠️Concerning: lack of ef…